Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Credit Rating
PPLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.3 pts more than Nifty Smallcap 250 and 0.6 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
CARE Ratings has upgraded Piramal Pharma's long-term bank facilities rating from CARE AA- (Positive) to CARE AA (Stable). The issuer rating and non-convertible debenture rating have also been upgraded from AA- to AA. Short-term bank facilities and commercial paper ratings have been reaffirmed at CARE A1+, the highest short-term rating. However, the outlook on long-term ratings has been revised from 'Positive' to 'Stable', suggesting CARE does not expect further upgrades in the near term. The upgrade reflects improved creditworthiness and financial profile of the company.
This is a positive signal for shareholders as the rating upgrade indicates stronger financial health, which could help the company raise debt at lower interest costs. However, the shift from a Positive outlook to Stable may temper expectations of further near-term upgrades.